BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31900516)

  • 1. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.
    Jingjing Z; Lei M; Jie Z; Sha C; Yapeng H; Weimin Z; Chunluan Y
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1549-1558. PubMed ID: 31900516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment.
    Blonska M; Zhu Y; Chuang HH; You MJ; Kunkalla K; Vega F; Lin X
    Blood; 2015 Feb; 125(6):981-91. PubMed ID: 25533033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
    Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas.
    Papoudou-Bai A; Goussia A; Batistatou A; Stefanou D; Malamou-Mitsi V; Kanavaros P
    Leuk Lymphoma; 2016; 57(1):143-50. PubMed ID: 25813203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.
    Pon JR; Wong J; Saberi S; Alder O; Moksa M; Grace Cheng SW; Morin GB; Hoodless PA; Hirst M; Marra MA
    Nat Commun; 2015 Aug; 6():7953. PubMed ID: 26245647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC-DLBCL cells.
    Zhu L; Tang F; Lei Z; Guo C; Song Y; Huang J; Xia X
    Mol Carcinog; 2019 Dec; 58(12):2340-2352. PubMed ID: 31556968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
    Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGR1 Addiction in Diffuse Large B-cell Lymphoma.
    Kimpara S; Lu L; Hoang NM; Zhu F; Bates PD; Daenthanasanmak A; Zhang S; Yang DT; Kelm A; Liu Y; Li Y; Rosiejka A; Kondapelli A; Bebel S; Chen M; Waldmann TA; Capitini CM; Rui L
    Mol Cancer Res; 2021 Aug; 19(8):1258-1269. PubMed ID: 33980611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC.
    Zhao CC; Jiao Y; Zhang YY; Ning J; Zhang YR; Xu J; Wei W; Kang-Sheng G
    Cell Death Dis; 2019 Mar; 10(4):252. PubMed ID: 30874550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.